BioCentury | Mar 2, 2021
Deals

March 1 Quick Takes: OrbiMed raises $3.5B for three funds; plus AZ-Junshi and megarounds for WuXi Diagnostics, FogPharma, Tenaya, DTx

...to treat cancer. venBio Managing Partner Corey Goodman joined the company’s board as chairman. New investors Cormorant Asset Management...
...round led by RA Capital with participation from new investors Access Biotechnology, Citadel’s Surveyor Capital, Cormorant Asset Management...
BioCentury | Feb 27, 2021
Deals

Feb. 26 Quick Takes: Venrock leads Artiva’s crossover-laden $120M series B; plus Roivant-Silicon, Origin, Sino-Akeso, Tricida, LISCure

...B financing led by Venrock Healthcare Capital Partners. Other new investors participating included Acuta Capital Partners, Cormorant Asset Management...
BioCentury | Feb 22, 2021
Management Tracks

Fresh from $21B Gilead deal, Immunomedics vet Malik to lead newly rebranded precision medicines company Fore

...Pontifax, OrbiMed Advisors, HBM Healthcare Investments, Wellington Management, Cormorant Asset Management...
BioCentury | Feb 16, 2021
Finance

Medicxi, blue chip investors launch Centessa with $250M to take asset-centric companies further

...in the series A round. Besides the co-leaders of the round, other investors included Boxer Capital, Cormorant Asset Management...
...of employees: 120Funds raised: $250 millionInvestors: Medicxi, General Atlantic, Vida Ventures, Janus Henderson Investors, Boxer Capital, Cormorant Asset Management...
BioCentury | Feb 12, 2021
Emerging Company Profile

With $70M A round, Takeda deal, 5AM’s Ensoma aims for accessible cell and gene therapies via empty adenoviral vectors

...of employees: 20Funds raised: $70 millionInvestors: 5AM Ventures, F-Prime Capital, Takeda Ventures, Viking Global Investors, Cormorant Asset Management...
BioCentury | Feb 1, 2021
Deals

Seeing potential blockbusters, Horizon buys AstraZeneca spinout Viela for more than $3B

...$52.80. Participants in Viela’s June 2019 series B round included HBM Healthcare Investments, Viking Global Investors, Cormorant Asset Management...
BioCentury | Jan 29, 2021
Finance

Jan. 28 Quick Takes: Sana aims high in latest IPO prospectus; plus short interest in biotech, and fundings for Curevac, Design, Ukko, Encodia and more

...A program to treat Friedreich’s ataxia is due to enter the clinic next year. Existing investors Cormorant Asset Management...
BioCentury | Jan 21, 2021
Deals

Jan. 20 Quick Takes: Beam adds $260M; plus Lilly-Merus, Thermo Fisher-Mesa, Verve, Aclaris, ViGeneron-Daiichi Sankyo

...Friday of $113.04. The syndicate included Perceptive Advisors, Farallon Capital, Casdin Capital, Redmile Group and Cormorant Asset Management...
...led the round alongside co-leader Casdin Capital. Also participating were Redmile Group, Janus Henderson Investors, Cormorant Asset Management...
BioCentury | Jan 8, 2021
Finance

Crossovers back Affinivax in $236M round as more pipeline vaccines move toward clinic

...investors, Affinivax’s latest round included new investors T. Rowe Price, Wellington Management, affiliates of Blackrock, Cormorant Asset Management...
BioCentury | Jan 5, 2021
Finance

Immuneering, Terns, Ikena raise crossover rounds as IPO queue stands to grow again

...a record-setting year for NASDAQ listings in 2020.Cormorant Asset Management...
Items per page:
1 - 10 of 188
BioCentury | Mar 2, 2021
Deals

March 1 Quick Takes: OrbiMed raises $3.5B for three funds; plus AZ-Junshi and megarounds for WuXi Diagnostics, FogPharma, Tenaya, DTx

...to treat cancer. venBio Managing Partner Corey Goodman joined the company’s board as chairman. New investors Cormorant Asset Management...
...round led by RA Capital with participation from new investors Access Biotechnology, Citadel’s Surveyor Capital, Cormorant Asset Management...
BioCentury | Feb 27, 2021
Deals

Feb. 26 Quick Takes: Venrock leads Artiva’s crossover-laden $120M series B; plus Roivant-Silicon, Origin, Sino-Akeso, Tricida, LISCure

...B financing led by Venrock Healthcare Capital Partners. Other new investors participating included Acuta Capital Partners, Cormorant Asset Management...
BioCentury | Feb 22, 2021
Management Tracks

Fresh from $21B Gilead deal, Immunomedics vet Malik to lead newly rebranded precision medicines company Fore

...Pontifax, OrbiMed Advisors, HBM Healthcare Investments, Wellington Management, Cormorant Asset Management...
BioCentury | Feb 16, 2021
Finance

Medicxi, blue chip investors launch Centessa with $250M to take asset-centric companies further

...in the series A round. Besides the co-leaders of the round, other investors included Boxer Capital, Cormorant Asset Management...
...of employees: 120Funds raised: $250 millionInvestors: Medicxi, General Atlantic, Vida Ventures, Janus Henderson Investors, Boxer Capital, Cormorant Asset Management...
BioCentury | Feb 12, 2021
Emerging Company Profile

With $70M A round, Takeda deal, 5AM’s Ensoma aims for accessible cell and gene therapies via empty adenoviral vectors

...of employees: 20Funds raised: $70 millionInvestors: 5AM Ventures, F-Prime Capital, Takeda Ventures, Viking Global Investors, Cormorant Asset Management...
BioCentury | Feb 1, 2021
Deals

Seeing potential blockbusters, Horizon buys AstraZeneca spinout Viela for more than $3B

...$52.80. Participants in Viela’s June 2019 series B round included HBM Healthcare Investments, Viking Global Investors, Cormorant Asset Management...
BioCentury | Jan 29, 2021
Finance

Jan. 28 Quick Takes: Sana aims high in latest IPO prospectus; plus short interest in biotech, and fundings for Curevac, Design, Ukko, Encodia and more

...A program to treat Friedreich’s ataxia is due to enter the clinic next year. Existing investors Cormorant Asset Management...
BioCentury | Jan 21, 2021
Deals

Jan. 20 Quick Takes: Beam adds $260M; plus Lilly-Merus, Thermo Fisher-Mesa, Verve, Aclaris, ViGeneron-Daiichi Sankyo

...Friday of $113.04. The syndicate included Perceptive Advisors, Farallon Capital, Casdin Capital, Redmile Group and Cormorant Asset Management...
...led the round alongside co-leader Casdin Capital. Also participating were Redmile Group, Janus Henderson Investors, Cormorant Asset Management...
BioCentury | Jan 8, 2021
Finance

Crossovers back Affinivax in $236M round as more pipeline vaccines move toward clinic

...investors, Affinivax’s latest round included new investors T. Rowe Price, Wellington Management, affiliates of Blackrock, Cormorant Asset Management...
BioCentury | Jan 5, 2021
Finance

Immuneering, Terns, Ikena raise crossover rounds as IPO queue stands to grow again

...a record-setting year for NASDAQ listings in 2020.Cormorant Asset Management...
Items per page:
1 - 10 of 188